Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Background To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer.Methods Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durvalum...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e001378.full |
id |
doaj-700a8acb389245c1b3dbad4f81ca05f7 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carol I Geppert Arndt Hartmann Benjamin Frey Markus Eckstein Markus Hecht Antoniu Oreste Gostian Sandra Rutzner Jens von der Grün Thomas Illmer Matthias G Hautmann Gunther Klautke Simon Laban Thomas Brunner Axel Hinke Ina Becker Sabine Semrau Panagiotis Balermpas Wilfried Budach Heinrich Iro Rainer Fietkau |
spellingShingle |
Carol I Geppert Arndt Hartmann Benjamin Frey Markus Eckstein Markus Hecht Antoniu Oreste Gostian Sandra Rutzner Jens von der Grün Thomas Illmer Matthias G Hautmann Gunther Klautke Simon Laban Thomas Brunner Axel Hinke Ina Becker Sabine Semrau Panagiotis Balermpas Wilfried Budach Heinrich Iro Rainer Fietkau Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 Journal for ImmunoTherapy of Cancer |
author_facet |
Carol I Geppert Arndt Hartmann Benjamin Frey Markus Eckstein Markus Hecht Antoniu Oreste Gostian Sandra Rutzner Jens von der Grün Thomas Illmer Matthias G Hautmann Gunther Klautke Simon Laban Thomas Brunner Axel Hinke Ina Becker Sabine Semrau Panagiotis Balermpas Wilfried Budach Heinrich Iro Rainer Fietkau |
author_sort |
Carol I Geppert |
title |
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 |
title_short |
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 |
title_full |
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 |
title_fullStr |
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 |
title_full_unstemmed |
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 |
title_sort |
safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced hnscc: first results of checkrad-cd8 |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2020-07-01 |
description |
Background To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer.Methods Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durvalumab 1500 mg fix dose on day 5 and tremelimumab 75 mg fix dose on day 5. Patients with pathologic complete response (pCR) in the rebiopsy after induction treatment or at least 20% increase of intratumoral CD8+ cell density in the rebiopsy compared with baseline entered radioimmunotherapy with concomitant durvalumab/tremelimumab. The objective of this interim analysis was to analyze safety and efficacy of the chemoimmunotherapy-induction treatment before radioimmunotherapy.Results A total of 57 patients were enrolled, 56 were treated. Median pretreatment intratumoral CD8+ cell density was 342 cells/mm². After induction treatment, 27 patients (48%) had a pCR in the rebiopsy and further 25 patients (45%) had a relevant increase of intratumoral CD8+ cells (median increase by a factor of 3.0). Adverse event (AE) grade 3–4 appeared in 38 patients (68%) and mainly consisted of leukopenia (43%) and infections (29%). Six patients (11%) developed grade 3–4 immune-related AE. Univariate analysis computed p16 positivity, programmed death ligand 1 immune cell area and intratumoral CD8+ cell density as predictors of pCR. On multivariable analysis, intratumoral CD8+ cell density predicted pCR independently (OR 1.0012 per cell/mm², 95% CI 1.0001 to 1.0022, p=0.016). In peripheral blood CD8+ cells, the coexpression of programmed death protein 1 significantly increased especially in patients with pCR.Conclusions Single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab is feasible and achieves a high biopsy-proven pCR rate. |
url |
https://jitc.bmj.com/content/8/2/e001378.full |
work_keys_str_mv |
AT caroligeppert safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT arndthartmann safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT benjaminfrey safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT markuseckstein safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT markushecht safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT antoniuorestegostian safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT sandrarutzner safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT jensvondergrun safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT thomasillmer safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT matthiasghautmann safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT guntherklautke safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT simonlaban safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT thomasbrunner safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT axelhinke safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT inabecker safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT sabinesemrau safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT panagiotisbalermpas safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT wilfriedbudach safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT heinrichiro safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 AT rainerfietkau safetyandefficacyofsinglecycleinductiontreatmentwithcisplatindocetaxeldurvalumabtremelimumabinlocallyadvancedhnsccfirstresultsofcheckradcd8 |
_version_ |
1721305278201200640 |
spelling |
doaj-700a8acb389245c1b3dbad4f81ca05f72021-07-13T15:01:29ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-07-018210.1136/jitc-2020-001378Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8Carol I Geppert0Arndt Hartmann1Benjamin Frey2Markus Eckstein3Markus Hecht4Antoniu Oreste Gostian5Sandra Rutzner6Jens von der Grün7Thomas Illmer8Matthias G Hautmann9Gunther Klautke10Simon Laban11Thomas Brunner12Axel Hinke13Ina Becker14Sabine Semrau15Panagiotis Balermpas16Wilfried Budach17Heinrich Iro18Rainer Fietkau19Comprehensive Cancer Center Erlangen-EMN, Erlangen, Bayern, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Bayern, GermanyDepartment of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Bayern, GermanyDepartment of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Bayern, GermanyDepartment of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, GermanyDepartment of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt am Main, GermanyMedical Oncology Clinic Dresden Freiberg, Dresden, Saxony, GermanyDepartment of Radiation Oncology, Universität Regensburg, Regensburg, Bayern, GermanyDepartment of Radiation Oncology, Chemnitz Hospital, Chemnitz, Sachsen, GermanyDepartment of Otolaryngology - Head & Neck Surgery, Universität Ulm, Ulm, Baden-Württemberg, GermanyDepartment of Radiation Oncology, Otto von Guericke Universität Magdeburg, Magdeburg, Sachsen-Anhalt, GermanyClinical Cancer Research Consulting (CCRC), Düsseldorf, Nordrhein-Westfalen, GermanyDepartment of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, GermanyDepartment of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, GermanyDepartment of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt am Main, GermanyDepartment of Radiation Oncology, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Bayern, GermanyDepartment of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, GermanyBackground To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer.Methods Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durvalumab 1500 mg fix dose on day 5 and tremelimumab 75 mg fix dose on day 5. Patients with pathologic complete response (pCR) in the rebiopsy after induction treatment or at least 20% increase of intratumoral CD8+ cell density in the rebiopsy compared with baseline entered radioimmunotherapy with concomitant durvalumab/tremelimumab. The objective of this interim analysis was to analyze safety and efficacy of the chemoimmunotherapy-induction treatment before radioimmunotherapy.Results A total of 57 patients were enrolled, 56 were treated. Median pretreatment intratumoral CD8+ cell density was 342 cells/mm². After induction treatment, 27 patients (48%) had a pCR in the rebiopsy and further 25 patients (45%) had a relevant increase of intratumoral CD8+ cells (median increase by a factor of 3.0). Adverse event (AE) grade 3–4 appeared in 38 patients (68%) and mainly consisted of leukopenia (43%) and infections (29%). Six patients (11%) developed grade 3–4 immune-related AE. Univariate analysis computed p16 positivity, programmed death ligand 1 immune cell area and intratumoral CD8+ cell density as predictors of pCR. On multivariable analysis, intratumoral CD8+ cell density predicted pCR independently (OR 1.0012 per cell/mm², 95% CI 1.0001 to 1.0022, p=0.016). In peripheral blood CD8+ cells, the coexpression of programmed death protein 1 significantly increased especially in patients with pCR.Conclusions Single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab is feasible and achieves a high biopsy-proven pCR rate.https://jitc.bmj.com/content/8/2/e001378.full |